Tjoapack Expands in the U.S. and Europe

Tjoapack has announced a major expansion of its global operations, with new investments in both the United States and Europe aimed at strengthening its end-of-line pharmaceutical packaging capabilities. The company is scaling infrastructure to address rising demand for complex, regulated packaging solutions, particularly for injectables, oral solid doses, and temperature-sensitive biologics.

In the United States, Tjoapack is developing a new 170,000-square-foot facility adjacent to its existing site in Clinton, Tennessee, with completion targeted for early 2027. The facility will include a comprehensive GMP suite featuring advanced packaging, labeling, and serialization systems, along with expanded cold chain and ambient storage. The site is designed to support a wide range of pharmaceutical formats, including oral solid dose products such as bottles and blisters, as well as injectable formats like vials and auto-injectors.

The company has also commissioned two advanced injectables packaging lines at the Clinton facility, including a fully automated high-speed vial line with integrated labeling, cartoning, and serialization, capable of producing up to 20 million vials annually. A semi-automated auto-injector packaging line has also been introduced, offering end-to-end traceability and enhanced operational efficiency. To support growing demand for biologics, Tjoapack has expanded its GMP-compliant cold storage capacity by 2.5 times, adding significant controlled-temperature storage infrastructure.

In Europe, the company has expanded operations at its facility in Etten-Leur with the installation of a second oral solid dose bottle packaging line. The new system enhances production flexibility, supporting multiple packaging formats such as cartoning, leaflet insertion, and shrink wrapping. The European site has also increased its cold storage capacity, reflecting rising demand for temperature-sensitive pharmaceutical products across the region.

These developments highlight Tjoapack’s strategy to enhance throughput, improve packaging flexibility, and strengthen its position in global pharmaceutical supply chains. The investments are aligned with broader industry trends, including increasing demand for biologics, stricter regulatory requirements, and the need for advanced end-of-line packaging solutions.

According to Precedence Research, the Europe end-of-line packaging market size accounted for USD 2.61 billion in 2025 and is predicted to grow from USD 2.71 billion in 2026 to approximately USD 3.96 billion by 2035, expanding at a CAGR of 4.26% from 2026 to 2035 as rising demand for pharmaceutical packaging automation and cold chain solutions drives market growth.

A recent report by Precedence Research highlights that the Europe End-of-Line Packaging market is benefiting from increasing adoption of advanced packaging technologies, growth in biologics and specialty drugs, and rising emphasis on compliance, traceability, and efficient supply chain management.